Logo image of GENI

GENIUS SPORTS LTD (GENI) Stock Fundamental Analysis

NYSE:GENI - New York Stock Exchange, Inc. - GG00BMF1JR16 - Common Stock - Currency: USD

9.1  -0.43 (-4.51%)

After market: 9.7575 +0.66 (+7.23%)

Fundamental Rating

3

GENI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 135 industry peers in the Hotels, Restaurants & Leisure industry. While GENI seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, GENI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GENI has reported negative net income.
In the past year GENI had a positive cash flow from operations.
GENI Yearly Net Income VS EBIT VS OCF VS FCFGENI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -200M -400M -600M

1.2 Ratios

GENI has a worse Return On Assets (-10.11%) than 87.02% of its industry peers.
With a Return On Equity value of -13.20%, GENI perfoms like the industry average, outperforming 41.98% of the companies in the same industry.
Industry RankSector Rank
ROA -10.11%
ROE -13.2%
ROIC N/A
ROA(3y)-34.2%
ROA(5y)N/A
ROE(3y)-43.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GENI Yearly ROA, ROE, ROICGENI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Gross Margin of GENI (19.84%) is worse than 86.26% of its industry peers.
The Profit Margin and Operating Margin are not available for GENI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.84%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GENI Yearly Profit, Operating, Gross MarginsGENI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -50 -100 -150 -200

More info and screens

5

2. Health

2.1 Basic Checks

GENI does not have a ROIC to compare to the WACC, probably because it is not profitable.
GENI has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, GENI has an improved debt to assets ratio.
GENI Yearly Shares OutstandingGENI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 50M 100M 150M 200M
GENI Yearly Total Debt VS Total AssetsGENI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

GENI has an Altman-Z score of 6.81. This indicates that GENI is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.81, GENI belongs to the top of the industry, outperforming 90.84% of the companies in the same industry.
GENI has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.00, GENI belongs to the best of the industry, outperforming 92.37% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.81
ROIC/WACCN/A
WACC9%
GENI Yearly LT Debt VS Equity VS FCFGENI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

GENI has a Current Ratio of 1.50. This is a normal value and indicates that GENI is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.50, GENI is doing good in the industry, outperforming 70.99% of the companies in the same industry.
A Quick Ratio of 1.50 indicates that GENI should not have too much problems paying its short term obligations.
The Quick ratio of GENI (1.50) is better than 74.81% of its industry peers.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.5
GENI Yearly Current Assets VS Current LiabilitesGENI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.60% over the past year.
Looking at the last year, GENI shows a quite strong growth in Revenue. The Revenue has grown by 18.30% in the last year.
EPS 1Y (TTM)68.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%183.33%
Revenue 1Y (TTM)18.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%18.16%

3.2 Future

Based on estimates for the next years, GENI will show a very strong growth in Earnings Per Share. The EPS will grow by 33.66% on average per year.
Based on estimates for the next years, GENI will show a quite strong growth in Revenue. The Revenue will grow by 18.36% on average per year.
EPS Next Y57.28%
EPS Next 2Y41.06%
EPS Next 3Y33.66%
EPS Next 5YN/A
Revenue Next Year24.04%
Revenue Next 2Y19.61%
Revenue Next 3Y18.27%
Revenue Next 5Y18.36%

3.3 Evolution

GENI Yearly Revenue VS EstimatesGENI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M
GENI Yearly EPS VS EstimatesGENI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GENI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GENI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GENI Price Earnings VS Forward Price EarningsGENI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K -1.5K -2K -2.5K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GENI Per share dataGENI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

A more expensive valuation may be justified as GENI's earnings are expected to grow with 33.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.06%
EPS Next 3Y33.66%

More info and screens

0

5. Dividend

5.1 Amount

GENI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENIUS SPORTS LTD

NYSE:GENI (2/21/2025, 8:23:21 PM)

After market: 9.7575 +0.66 (+7.23%)

9.1

-0.43 (-4.51%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-07 2025-03-07/amc
Inst Owners72.38%
Inst Owner Change9.69%
Ins Owners11.72%
Ins Owner ChangeN/A
Market Cap2.29B
Analysts82.22
Price Target11.77 (29.34%)
Short Float %14.18%
Short Ratio13.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)179.72%
Min EPS beat(2)-205.21%
Max EPS beat(2)564.64%
EPS beat(4)1
Avg EPS beat(4)68.26%
Min EPS beat(4)-205.21%
Max EPS beat(4)564.64%
EPS beat(8)1
Avg EPS beat(8)-33.07%
EPS beat(12)3
Avg EPS beat(12)-16.94%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-0.8%
Min Revenue beat(2)-0.92%
Max Revenue beat(2)-0.68%
Revenue beat(4)1
Avg Revenue beat(4)-0.59%
Min Revenue beat(4)-1.15%
Max Revenue beat(4)0.41%
Revenue beat(8)3
Avg Revenue beat(8)0.67%
Revenue beat(12)6
Avg Revenue beat(12)1.85%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)23.46%
EPS NQ rev (1m)1.99%
EPS NQ rev (3m)180.69%
EPS NY rev (1m)3.41%
EPS NY rev (3m)30.08%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)5.22%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.95
P/FCF N/A
P/OCF 118.83
P/B 4.12
P/tB 20.04
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)0.08
OCFY0.84%
SpS1.84
BVpS2.21
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.11%
ROE -13.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.84%
FCFM N/A
ROA(3y)-34.2%
ROA(5y)N/A
ROE(3y)-43.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 74.83%
Cap/Sales 13.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.5
Quick Ratio 1.5
Altman-Z 6.81
F-Score6
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)63.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)12.85%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%183.33%
EPS Next Y57.28%
EPS Next 2Y41.06%
EPS Next 3Y33.66%
EPS Next 5YN/A
Revenue 1Y (TTM)18.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%18.16%
Revenue Next Year24.04%
Revenue Next 2Y19.61%
Revenue Next 3Y18.27%
Revenue Next 5Y18.36%
EBIT growth 1Y-2.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year257.55%
EBIT Next 3Y68.5%
EBIT Next 5Y49.24%
FCF growth 1Y26.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y348.72%
OCF growth 3YN/A
OCF growth 5YN/A